We have previously reported that the key apoptosis related gene caspase 8 (CASP8) is frequently silenced in small cell lung cancer (SCLC) tumors and cell lines usually, but not always, by aberrant promoter methylation. Because CASP8 is a key component of the deathinducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines. MYC family members are frequently amplified (MYC+ve) in SCLC, and MYC is a potent inducer of apoptosis. We examined 34 SCLC lines (12 of which were MYC+ve) and 22 NSCLC lines. CASP8 gene expression was frequently lost (79%) at message and protein levels in SCLC but not in non-SCLC (NSCLC). MYC amplification was present in 45% of SCLC cell lines, which had lost CASP8 expression, but not in any of the CASP8 positive lines. The frequency of CASP8 loss was significantly higher in MYC+ve SCLC compared to MYC7ve SCLC or in NSCLC. Analyses of other DISC components showed significantly higher rates of loss of expression of CASP10, DR5, FAS and FASL in SCLC compared to NSCLC. The loss of expression of proapoptotic DISC components was significantly higher in MYC+ve SCLC cell lines and these lines were completely resistant to TRAIL. Expression of CASP10 (a caspase closely related to CASP8) was frequently absent at the protein level in both SCLC and NSCLC lines. Expression of c-FLIP (proteolytically inactive homolog of CASP8) was inversely related to expression of CASP8. Our major conclusions are: (a) The death receptor pathway is differently inactivated at multiple levels in lung cancer cell lines; and (b) MYC amplification in SCLC is associated with inactivation of most components of the DISC complex, with resistance to TRAIL and with expression of c-FLIP. These findings may have considerable clinical and therapeutic implications.
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The other pathway involves death inducing ligands (TNFa, Fas ligand or FasL and TRAIL) and their receptors (including the TRAIL receptors DR4 and DR5) (Schneider and Tschopp, 2000) . Ligand-receptor binding recruits the adaptor protein FADD and results in activation of the key caspase (CASP8) with formation of the death inducing signaling complex (DISC). We recently demonstrated that both CASP8 and the closely related caspase CASP10 can each initiate apoptosis independently of the other (Kischkel et al., 2001) . Activation of either of the initiator pathways (death receptor or mitochondrial) results in activation of the executioner pathway and results in apoptosis. Flice inhibitory protein (c-FLIP) is a recently identified intracellular protein, which is structurally similar to CASP8 and contains the FADD-binding prodomain but lacks the ability to initiate the executioner pathway (Thome and Tschopp, 2001 ).
Amplification of MYC family genes (c-MYC, N-MYC and L-MYC) is common in certain cancers including SCLC but rare in NSCLC . The MYC family of proteins are known for their potent apoptotic properties (Prendergast, 1999) . Neuroblastomas, especially those with N-MYC amplification, frequently inactivate CASP8 by aberrant promoter methylation (Teitz et al., 2000) . We have recently demonstrated that CASP8 is differently inactivated in lung cancers, usually, but not always, by aberrant promoter methylation (Shivapurkar, 2002) . Based on our preliminary data, we explored expression and function of the DISC complex components in lung cancer cell lines and their relationship to MYC amplification.
In this study we have focused on the receptor mediated pathway because previous studies by us (Shivapurkar et al., 2002) and another laboratory (Joseph et al., 1999) indicated that this pathway is deregulated in lung cancer at multiple levels. Of the death inducing ligands, the TNF-related apoptosisinducing ligand (TRAIL) is of particular interest. TRAIL is a rare example of a molecule which specifically kills many transformed and cancer cells, but not most normal cells (Ashkenazi and Dixit, 1998) . Thus, it has been proposed as a therapeutic agent for cancer. Because disruption of the DISC pathway would result in resistance to TRAIL, dissecting this pathway is of potential clinical importance. We studied expression of the DISC components and resistance to TRAIL in a panel of 34 SCLC lines (12 of which were MYC+ve) and 22 NSCLC lines. RNA expression studies (by RT -PCR) demonstrated frequent losses of CASP8, CASP10, DR5 and Fas in SCLC lines (435%) (Figures 1a and 2a ). Corresponding losses in NSCLC were always lower than in SCLC, and the differences were significant for CASP8, CASP10 and Fas. Only DR5 expression was lost at a rate greater than 35% in NSCLC. There was considerable duplication in the gene loss patterns. Thus 13 out of 34 (38%) of SCLC lines had lost both CASP8 and CASP10. In contrast none of the NSCLC lost either molecule. While losses in TRAIL receptor gene expression was mostly limited to DR5, 9 out of 56 (16%) of the lung cancer cell lines had loss of expression of both receptors. In addition, 11% of lung cancer cell lines had loss of expression of both Fas and FasL. The mean number of DISC components (n=7) lost in SCLC lines was 3.3 and in NSCLC it was 1.4. At least one DISC component was lost in 31 out of 34 SCLC lines (91%) while the comparable figure for NSCLC was 9 out of 22 (41%). These differences were significant (P50.05). MYC amplified SCLC cell lines had significantly higher rates of loss for CASP8, CASP10, DR5, Fas and FasL (Figures 1b and 2a) . For SCLC MYC+ve lines, the mean number of DISC components lost was 5.3 and for SCLC MYC7ve lines, the mean number of DISC components lost was 2.1 (P50.05).
Since we have recently demonstrated that CASP8 is differentially inactivated in lung cancers by aberrant promoter methylation (Shivapurkar et al., 2002) , we examined the role of methylation in the silencing of the other DISC components. SCLC cell lines with losses in expression of one or more DISC components were treated with Aza-CdR and cDNA prepared by RT -PCR were tested for gene expression (Shivapurkar et al., 2002) . Our results showed that six out of 10 SCLC with loss of CASP8 showed re-expression of CASP8 (Figure 2b) . However, none of these 10 SCLC lines which also lost CASP10 showed re-expression of CASP10. For the other DISC components, gene reexpression was noted for 0 out of 6 for DR4 and DR5, 0 out of 5 for FasL and 2 out of 6 for Fas. Thus, except for CASP8, methylation does not appear to be a major mechanism for gene silencing of the DISC components studied. All the SCLC cell lines showing re-expression of CASP8, also showed methylation of promoter region (Figure 2c ) confirming that methylation was the mechanism of gene silencing.
Because of our previous finding that there was discordance between expression of CASP10 RNA and protein expression (Kischkel et al., 2001) , we correlated RNA and protein expression for CASP8 and CASP10 (Figure 3a) . We studied 34 SCLC cell lines for the . Total RNA was extracted and purified from cells as described before (Shivapurkar et al., 2002) . RT was performed on total RNA using two rounds of PCR as described using SUPERSCRIPT II reverse transcriptase and Hot start as described before (Shivapurkar et al., 2002) . Statistical differences between groups were examined using Fisher's exact probability test and Wilcoxon/Kruskal -Wallis test. Values of P50.05 were considered significant Protein expression studies for the long form of c-FLIP (c-FLIP L ), its major isoform, demonstrated an inverse relationship with expression of CASP8 ( Figure  3b ). SCLC lines lacking CASP8 expression (including all 12 MYC+ve lines and four of 13 MYC7ve lines) expressed c-FLIP L . All 20 NSCLC lines expressing CASP8 lacked expression of c-FLIP L .
We tested the sensitivity of lung cancer cells to cell killing by TRAIL and correlated the data with inactivation of DISC components (Figure 4 ). Six SCLC cell lines inactivating four or more components were completely resistant to TRAIL. This group included all four MYC+ve cell lines tested. All five Figure 1a ). All cell lines are preceded by the prefix NCI-, H524 represents a MYC +ve SCLC cell line that had lost seven key components of DISC. H460 represents a NSCLC cell line, which retained expression of all seven DISC components tested. The other four cell lines show differential patterns of loss. The primers and experimental conditions were as described before (Griffith et al., 1998; Hopkins-Donaldson et al., 2000; Ng et al., 1999; O'Connell et al., 1996) . (b) Re-expression of CASP and CASP10 as demonstrated by RT -PCR after Aza-CdR treatment (Shivapurkar et al., 2002) . We demonstrate re-expression of CASP8 in three SCLC cell lines lacking expression of the gene (left panel), indicating that promoter methylation was the probable mechanism of gene silencing. Two of the cell lines (H524 and H592) also lacked expression of CASP10. AzaCdR treatment did not restore gene expression (right panel) indicating that promoter methylation was probably not the cause of gene silencing. GAPDH expression was used as a control for RNA integrity. (c) Methylation analysis of CASP8. Three SCLC cell lines demonstrate only the methylated form, while two NSCLC lines (H1703 and H460) express only the unmethylated form Our data demonstrate that the death receptor pathway to apoptosis is deregulated in most lung cancer cell lines, although there are major differences between SCLC and NSCLC. In SCLC a mean of nearly 50% of the seven DISC components examined were lost, while in NSCLC the number was significantly lower (P50.03). In SCLC, the DISC components most frequently lost were CASP8, CASP10, DR5 and Fas. By contrast, DR5 was the component most frequently lost at the RNA level in NSCLC. However, Western blot demonstrated frequent loss of CASP10 at the protein level, indicating either a failure of translation or rapid degradation of the protein. All SCLC lines had lost CASP10 expression, either at transcriptional or translational levels. TRAIL expression was absent in normal bronchial epithelium, and we did not study its expression in lung cancer cell lines. MYC over expression is a potent stimulator of apoptosis, and MYC amplified SCLC lines had significantly higher rates of loss of DISC components than MYC7ve lines. Of interest, MYC amplified SCLC lines ('variant' lines) demonstrate considerable resistance to radiation (Morstyn et al., 1984) , a finding that may be related to their resistance to apoptotic signals. MYC amplified lines are relatively uncommon, and the vast majority of the ones we established were from patients who had previously received cyclophosphamide based chemotherapy. Although the clinical role of MYC amplification in SCLC tumors from previously untreated specimens is unknown, these cell lines provide useful in vitro models to study the interplay between MYC over expression and apoptosis. However, modest over expression of MYC (without amplification or with low level amplification) is frequent in NSCLC (Broers et al., 1993; Ozkara et al., 1999; Zajac-Kaye, 2001 ). In these tumors inactivation of DISC components may result in varying degrees of resistant to TRAIL and other apoptotic stimuli and be essential for survival.
We noted an inverse relationship between protein expression of c-FLIP and CASP8. In addition to being an enzymatically inactive homolog of CASP8, we have demonstrated that c-FLIP can activate the NF-kB pathway (Chaudhary et al., 2000; Kataoka et al., 2000) , which has been shown to protect against druginduced apoptosis (Kumar et al., 2001) . Thus, over expression of c-FLIP may result not only in avoidance of apoptosis but also in chemoresistance.
Why do lung cancer cell lines, especially SCLC, inactivate multiple components of the death receptor pathway? We demonstrated a relationship between loss of increasing numbers of DISC components and resistant to TRAIL. Thus, full resistance to death ligands apparently requires deregulation of the pathway at multiple levels. Of interest, differential sensitivity to apoptosis has been reported for SCLC and NSCLC (Joseph et al., 1999) , indicating that SCLC are under increased pressure to undergo apoptotic death, and require multiple mechanisms for survival. The increased proapoptotic pressure from MYC amplification requires dismantling of all or almost all of death receptor pathway.
In summary, SCLC and NSCLC cell lines have differentially acquired resistance to death receptors at multiple levels. These findings may have considerable clinical and therapeutic implications.
Abbreviations SCLC, small cell carcinoma; NSCLC, non small cell carcinoma Figure 4 Sensitivity of 11 SCLC and six NSCL cell lines to TRAIL. Cells were cultured in RPMI medium supplemented with 5% fetal bovine serum at 378C with 5% CO 2 . Cells (1610 4 in 100 ml culture medium per well) were seeded in 96 flat bottom well plates, treated with recombinant TRAIL (100 ng/ml) (prepared by PMC) for 48 h. For cell survival assays, 20 ml of MTS reagent (final concentration 333 ml/ml MTS and 25 mM of MTS reagent (final concentration 333 ml/ml MTS and 25 mM PMS, Promega, Madison, WI, USA) per well was added and plates were incubated for further 2 -3 h at 378C and 5% CO 2 . Absorbance of viable cells was measured at 490 nm with 600 nm as a reference wavelength. Sensitivity to TRAIL was measured as percentage survival compared to the untreated control. Numbers in brackets next to cell line symbols represent the number of DISC components with loss of expression in the individual cell lines
